Adavosertib is the first-in-class WEE1 inhibitor that has shown antitumor efficacy with the best response in ovarian and endometrial cancers.26 As Wee1-AS led to increased mitochondrial function and improved signs of MASLD, we asked whether adavosertib had beneficial effects on MASLD in mice. Here, WEE1 is linked to endometrial cancer.